Cargando…
Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997347/ https://www.ncbi.nlm.nih.gov/pubmed/32015343 http://dx.doi.org/10.1038/s41408-020-0278-5 |
| _version_ | 1783493676657278976 |
|---|---|
| author | Leng, Siyang Bhutani, Divaya Raza, Shahzad Assal, Amer Pan, Samuel Hu, Jianhua Wei, Alexander Mapara, Markus Lentzsch, Suzanne |
| author_facet | Leng, Siyang Bhutani, Divaya Raza, Shahzad Assal, Amer Pan, Samuel Hu, Jianhua Wei, Alexander Mapara, Markus Lentzsch, Suzanne |
| author_sort | Leng, Siyang |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6997347 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-69973472020-02-11 Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma Leng, Siyang Bhutani, Divaya Raza, Shahzad Assal, Amer Pan, Samuel Hu, Jianhua Wei, Alexander Mapara, Markus Lentzsch, Suzanne Blood Cancer J Correspondence Nature Publishing Group UK 2020-02-03 /pmc/articles/PMC6997347/ /pubmed/32015343 http://dx.doi.org/10.1038/s41408-020-0278-5 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Correspondence Leng, Siyang Bhutani, Divaya Raza, Shahzad Assal, Amer Pan, Samuel Hu, Jianhua Wei, Alexander Mapara, Markus Lentzsch, Suzanne Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma |
| title | Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma |
| title_full | Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma |
| title_fullStr | Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma |
| title_full_unstemmed | Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma |
| title_short | Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma |
| title_sort | phase i/ii study of carfilzomib, bendamustine, and dexamethasone (cbd) in patients with newly diagnosed multiple myeloma |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997347/ https://www.ncbi.nlm.nih.gov/pubmed/32015343 http://dx.doi.org/10.1038/s41408-020-0278-5 |
| work_keys_str_mv | AT lengsiyang phaseiiistudyofcarfilzomibbendamustineanddexamethasonecbdinpatientswithnewlydiagnosedmultiplemyeloma AT bhutanidivaya phaseiiistudyofcarfilzomibbendamustineanddexamethasonecbdinpatientswithnewlydiagnosedmultiplemyeloma AT razashahzad phaseiiistudyofcarfilzomibbendamustineanddexamethasonecbdinpatientswithnewlydiagnosedmultiplemyeloma AT assalamer phaseiiistudyofcarfilzomibbendamustineanddexamethasonecbdinpatientswithnewlydiagnosedmultiplemyeloma AT pansamuel phaseiiistudyofcarfilzomibbendamustineanddexamethasonecbdinpatientswithnewlydiagnosedmultiplemyeloma AT hujianhua phaseiiistudyofcarfilzomibbendamustineanddexamethasonecbdinpatientswithnewlydiagnosedmultiplemyeloma AT weialexander phaseiiistudyofcarfilzomibbendamustineanddexamethasonecbdinpatientswithnewlydiagnosedmultiplemyeloma AT maparamarkus phaseiiistudyofcarfilzomibbendamustineanddexamethasonecbdinpatientswithnewlydiagnosedmultiplemyeloma AT lentzschsuzanne phaseiiistudyofcarfilzomibbendamustineanddexamethasonecbdinpatientswithnewlydiagnosedmultiplemyeloma |